Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
Frontiers in Pharmacology · 09.01.2023 · 13
DOI: 10.3389/fphar.2022.1077468 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.01.2023. Verfasst von Zherui Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, China. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded indication and increased use of Immune checkpoint inhibitors have resulted in increased reports of toxicity called immune-related adverse events (irAEs). Due to the unique immunological characteristics of the liver, a hepatic immune-related adverse events has also been reported, which is usually termed Immune-mediated hepatitis (IMH). So far, it is generally considered that the mechanism of IMH induced by Immune checkpoint inhibitors is mainly the overactivation of T cells. It has been reported that the incidence of IMH ranges from 1% to 15%. Because of the lack of specific markers, a diagnosis of exclusion of IMH is critical. Although most IMH is mild and recoverable, several death cases have been reported, which has been increasingly concerned. This review summarizes the current understanding of the pathophysiology, epidemiology, diagnosis, management and prognosis of IMH caused by Immune checkpoint inhibitors. It also discusses the controversial issues in IMH, such as the role of liver biopsy, grading criteria, risk factors, rational treatment strategies with steroids, and the timing of Immune checkpoint inhibitors rechallenging, which may provide helpful information for IMH in future clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical School of Chinese PLA, Beijing, China.
- Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023). Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1077468
Vancouver
Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1077468
BibTeX
@article{Liu2023,
author = {Liu, Zherui and Zhu, Yun and Xie, Huan and Zou, Zhengsheng},
title = {Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {13},
doi = {10.3389/fphar.2022.1077468}
}
EUVIMED